Search | Clinical Trials Finder

Conditions: Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more

Conditions: Multiple Myeloma
Interventions: Pembrolizumab, Daratumumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Jacksonville, Florida • Atlanta, Georgia • Bloomfield Hills, Michigan

Conditions: Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions: durvalumab, carboplatin AUC 2/paclitaxel, External beam radiation (EBRT), esophagogastrectomy, Tremelimumab; Biological · Drug · Radiation + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 4 more

Conditions: Advanced Triple Negative Breast Cancer
Interventions: N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy, Cyclophosphamide; Biological · Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Interventions: Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 738 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 23
States / cities: Los Angeles, California • Monterey, California • Orange, California + 19 more

Conditions: Neoplasms, Head and Neck
Interventions: Dostarlimab, Belrestotug, Nelistotug, Remzistotug; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: New Haven, Connecticut • Iowa City, Iowa • St Louis, Missouri + 2 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: St Louis, Missouri • Nashville, Tennessee • Houston, Texas

Conditions: Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
Interventions: V941, Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 10
States / cities: Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more

Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions: Trilaciclib, Placebo, Gemcitabine, Carboplatin; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more

Conditions: Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Interventions: Reduced Dose of Chemotherapy and Immunotherapy; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 2
States / cities: Richmond, Virginia • Tappahannock, Virginia

Conditions: Oropharyngeal Squamous Cell Carcinoma
Interventions: Pembrolizumab, Nivolumab; Drug
Lead sponsor: Hookipa Biotech GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dublin, Ohio

Conditions: Endometrial Cancer, Ovarian Cancer
Interventions: PD-1/PDL-1 staining; Diagnostic Test
Lead sponsor: RWJ Barnabas Health at Jersey City Medical Center; Other
Eligibility: Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Rectal Cancer
Interventions: durvalumab; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 43
States / cities: Guilford, Connecticut • New Haven, Connecticut • North Haven, Connecticut + 25 more

Conditions: Small Cell Lung Cancer
Interventions: YL201, Tarlatamab, Durvalumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Irvine, California • New Haven, Connecticut • Tampa, Florida + 7 more

Conditions: Esophageal Neoplasms
Interventions: Pembrolizumab, Placebo, Cisplatin, 5-FU; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 749 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 12
States / cities: West Los Angeles, California • Chicago, Illinois • Westwood, Kansas + 9 more

Conditions: Stage IV NSCLC
Interventions: Poly ICLC, IVIG; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 52
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 49 more

Conditions: Triple-Negative Breast Cancer (TNBC)
Interventions: BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Standard-of-care chemotherapy, Losartan and aspirin; Drug
Lead sponsor: BreakBio Corp; Industry
Eligibility: 18 Years to 72 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions: M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine; Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Solid Tumors
Interventions: MEDI4736, tremelimumab; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 30
States / cities: Scottsdale, Arizona • Duarte, California • La Jolla, California + 23 more

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions: Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy; Radiation · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 56
States / cities: Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more

Conditions: Melanoma, Head and Neck Squamous Cell Carcinoma
Interventions: TILT-123, Avelumab; Biological · Drug
Lead sponsor: TILT Biotherapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 623 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 18
States / cities: Anchorage, Alaska • Chandler, Arizona • Bakersfield, California + 15 more

Conditions: Gastric Cancer, Peritoneal Carcinomatosis
Interventions: Cisplatin, Mitomycin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

Tumor Grade Determines PD-1/PDL-1 Expression

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer